ArticleCurrent microbiology2025
Ribosome Engineering for Enhanced Butenyl-Spinosyn Production in Saccharopolyspora pogona.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Ribosome engineering, a strategy that utilizes antibiotic resistance mutations to modulate ribosomal function, has emerged as a powerful approach for enhancing microbial metabolite production. In this study, ribosome engineering was applied to Saccharopolyspora pogona ASAGF2-G4 under streptomycin selection to improve butenyl-spinosyn production. Screening for streptomycin-resistant mutants at concentrations ranging from 2 to 20 µg/mL resulted in the isolation of 58 mutants, of which 27.6% exhibited increased butenyl-spinosyn production. Among these, 22 mutants harbored six distinct mutations in the rpsL gene, resulting in five amino acid substitutions in the ribosomal protein S12: Lys43 to Arg, Lys43 to Thr, Lys43 to Asn, Lys88 to Glu, and Lys88 to Arg. The highest frequency of rpsL mutant isolation was observed at a streptomycin concentration of 15 µg/mL. Phenotypic characterization revealed altered growth dynamics, pH shifts, and glucose utilization among the mutants, with the K88R and K43R variants exhibiting significantly increased butenyl-spinosyn production-1.78-fold and 1.64-fold higher than that of the parental strain, respectively. Quantitative PCR analysis showed significant upregulation of translation-related genes (rpsL and frr), growth-related genes (whiA and bldD), and key butenyl-spinosyn biosynthetic genes (busA, busF, and busI) in the K88R mutant, suggesting that the K88R substitution enhances target compound biosynthesis by modulating ribosomal function and associated metabolic networks. Future research should explore combinatorial approaches, including the development of multi-antibiotic-resistant mutants and elevated expression of ribosomal genes, to maximize butenyl-spinosyn yields. This study underscores the potential of ribosome engineering as a platform for improving butenyl-spinosyn production and provides a foundation for subsequent industrial-scale applications.
Indexed as
Identifiers
40526196What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.